Biogen turns to telehealth company to boost its postpartum depression drug
Oct. 8, 2024
Health Tech Correspondent
As Biogen aims to grow sales of postpartum depression drug Zurzuvae, it’s turning to well-funded telehealth company Talkiatry to boost awareness of and care for the often overlooked condition.
Under the deal, Talkiatry, which recently raised $130 million and employs over 350 psychiatrists, created a new landing page on its website with information about postpartum depression. From there, visitors can take an intake assessment that funnels them into Talkiatry’s care programs. The Zurzuvae website will include a link to the landing page. The terms of the deal were not disclosed.
advertisement
According to the CDC, 1 in 8 people experience postpartum depression after giving birth, with symptoms that may include sadness or guilt or a desire to harm oneself. Many do not receive adequate care, with potential long-term impacts on the health of parents and newborns.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 months Get StartedThen $399/year
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe Log In Biogen, Mental Health, STAT+, Telehealth Submit a correction requestReprints
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
